SCHEMBL1825539

SCHEMBL1825539

CCOC(=O)C(NCc1ccccc1)c1ccc(OS(C)(=O)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
ADRB3 P13945 1/20 0.41
PPARG P37231 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GPR88 Q9GZN0 1/20 0.40
LMNA P02545 1/20 0.40
CNR2 P34972 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
PPID Q08752 1/20 0.40
MMP8 P22894 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1826255 0.91 MEN1 (0.50) MEN1KMT2AADRB3PPARG
SCHEMBL1824594 0.90 MEN1 (0.62) MEN1KMT2AADRB3L3MBTL1CNR2
SCHEMBL1826615 0.88 MEN1 (0.48) MEN1KMT2ASMN1; SMN2GPR88LMNA
SCHEMBL1828570 0.87 MEN1 (0.49) MEN1KMT2AADRB3GPR88CNR2
SCHEMBL1823682 0.86 MEN1 (0.48) MEN1KMT2AADRB3PPARG
SCHEMBL1826184 0.85 KMT2A (0.46) MEN1KMT2ASMN1; SMN2PPARGL3MBTL1
SCHEMBL1826461 0.83 ATM (0.54) PPARGL3MBTL1LMNA
SCHEMBL1824442 0.83 PPID (0.43) MEN1KMT2ASMN1; SMN2PPARGLMNA
SCHEMBL1822769 0.82 PPARG (0.47) SMN1; SMN2PPARGL3MBTL1MMP8MMP2
SCHEMBL1822770 0.82 PPARG (0.47) SMN1; SMN2PPARGL3MBTL1MMP8MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 MEN1 421/4885KMT2A 1068/4885SMN1; SMN2 2274/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 MEN1 183/4885KMT2A 1084/4885SMN1; SMN2 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.